drugset / Trial / NCT06859853
A Study to Evaluate MWN109 Injection in Healthy Subjects
RandomizedSequentialQuadruple-blindTreatment
Summary
This study is a Phase1, randomized, double-blinded, and placebo-controlled study. In each cohort, enrolled participants will be randomized to receive either placebo or MWN109.
Timeline
- Start
- 2025-03-17
- Primary completion
- 2025-09-25
- Completion
- 2025-11-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | MWN109 | Unknown | 0.25 mg | Subcutaneous |
| Comparator | MWN109 | Unknown | 0.75 mg | Subcutaneous |
| Comparator | MWN109 | Unknown | 1.5 mg | Subcutaneous |
| Comparator | MWN109 | Unknown | 3 mg | Subcutaneous |
| Comparator | MWN109 | Unknown | 6 mg | Subcutaneous |
| Comparator | MWN109 | Unknown | 9 mg | Subcutaneous |